Evidence map›Paper›PMID 42326014›Full record

ArticleFrontiers in cell and developmental biology2026

Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma.

Amaya Lopez-Pascual, Jasmin Elurbide, Emiliana Valbuena-Goiricelaya, M Ujue Latasa, Elena Anaya, Elena Adan-Villaescusa, Borja Castelló-Uribe, Luz A Martínez-Pérez, Iker Uriarte, Maria Arechederra and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Amaya Lopez-PascualHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Jasmin ElurbideHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Emiliana Valbuena-GoiricelayaHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
M Ujue LatasaHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Elena AnayaHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Elena Adan-VillaescusaHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Borja Castelló-UribeHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Luz A Martínez-PérezHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Iker UriarteHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Maria ArechederraHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Sergio CiordiaFunctional Proteomics Laboratory, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
Fernando J CorralesFunctional Proteomics Laboratory, Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
Pavel StrnadMedical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
Sona FrankovaDepartment of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
Eva SticovaClinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia.
Ondrej FabianClinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia.
Leticia ColynMax Plank Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Patricia InacioMax Plank Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Juan BayoPrograma de Hepatología Experimental y Terapia Génica, Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, CONICET-Universidad Austral, Buenos Aires, Argentina.
Meritxell HuchMax Plank Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Carmen BerasainHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Maite G Fernández-BarrenaHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Matías A AvilaHepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Epigenetic alterations play an increasingly recognized role in carcinogenesis and in the development of resistance to anticancer therapies. Epigenetic enzymes (writers and erasers) and effectors (readers) are largely influenced by the availability of metabolites generated through one-carbon metabolism (OCM), the tricarboxylic acid (TCA) cycle, and acetyl-CoA synthesis (ACS). In this study we examined the expression of epigenetic and metabolic genes to investigate their interplay in cholangiocarcinoma (CCA). Method: We examined 257 epigenetic genes (EpiGs), 96 metabolic genes (MGs), and 189 rate-limiting enzymes (RLEs) in transcriptomic data from iCCA, eCCA, and normal bile ducts, healthy liver-derived organoids, and CCA tumoroids, alongside prognostic signatures. CRISPR-Cas9 DepMap data evaluated the impact of EpiGs and MGs on cell viability. HuCCT-1 iCCA cells were exposed to hypoxia (1% O Results: Several EpiGs were upregulated in iCCA and eCCA, including writers ( Conclusion: EpiGs and MGs are markedly altered in both human and experimental CCA, with several changes particularly enriched in aggressive molecular subclasses associated with poor prognosis. We observed substantial rewiring of epigenetic cofactor-related MG expression in CCAs. Functional assays validated new targets among EpiGs (e.g.,

Indexed as

cholangiocarcinomadrug targetsepigeneticsmetabolismmouse models

Identifiers

PMID42326014
PMCPMC13275250

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.